CD274 and cancer: However, while clinical trials using antibodies targeting PD-1 and its ligand B7-H1/PD-L1 have resulted in the regulatory approval for use of multiple antibodies for multiple cancer types, clinical trials with Ipilimumab have met high profile failures in multiple phase III clinical trials, due to considerably higher toxicity, including fatal ones [6,7,8].